US Needed Simple Pragmatic COVID-19 Trial For Repurposing Candidates, Woodcock Says
One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.
You may also be interested in...
For Lilly’s Donanemab, US FDA Commissioner Is Already Thinking About Post-Market Questions
From positive topline data to Robert Califf weighing in on the right patient population to treat with the Alzheimer’s candidate in less than a day, the drug rejected by the agency for accelerated approval earlier this year looks to make a quick comeback.
How Should The US Government Coordinate Emergency Clinical Trials?
Research institutions, CROs, biopharma industry and other stakeholders are asked to comment on potential governance structure that would determine when trials are needed to address disease outbreaks and other public health emergencies.
Would Biden’s ‘Advanced Research’ Projects Mesh Well At NIH?
HHS Secretary Becerra answers questions about the scope of the proposed ARPA-H agency; more to come during NIH budget hearing.